cell division. Gilman *et al*., Goodman and Gilman's: *The Pharmacological Basis of Therapeutics*, Tenth Ed. (McGraw Hill, New York).

[10] Despite availability of a variety of chemotherapeutic agents, chemotherapy has many drawbacks. Stockdale, *Medicine*, vol. 3, Rubenstein and Federman, eds., ch. 12, sect. 10, 1998. Almost all chemotherapeutic agents are toxic, and chemotherapy causes significant, and often dangerous side effects including severe nausea, bone marrow depression, and immunosuppression. Additionally, even with administration of combinations of chemotherapeutic agents, many tumor cells are resistant or develop resistance to the chemotherapeutic agents. In fact, those cells resistant to the particular chemotherapeutic agents used in the treatment protocol often prove to be resistant to other drugs, even if those agents act by different mechanism from those of the drugs used in the specific treatment. This phenomenon is referred to as pleiotropic drug or multidrug resistance. Because of the drug resistance, many cancers prove or become refractory to standard chemotherapeutic treatment protocols.


[11] Other diseases or conditions associated with, or characterized by, undesired angiogenesis are also difficult to treat. However, some compounds such as protamine, hepain and steroids have been proposed to be useful in the treatment of certain specific diseases. Taylor *et al*., *Nature* 297:307 (1982); Folkman *et al*., *Science* 221:719 (1983); and U.S. Pat. Nos. 5,001,116 and 4,994,443.

[12] Still, there is a significant need for safe and effective methods of treating, preventing and managing cancer and other diseases and conditions, including for diseases that are refractory to standard treatments, such as surgery, radiation therapy, chemotherapy and hormonal therapy, while reducing or avoiding the toxicities and/or side effects associated with the conventional therapies.

3. SUMMARY

[13] Provided herein are 4'-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates (*e.g.*, hydrates), prodrugs, clathrates, or stereoisomers thereof.

[13a] In one aspect of the present disclosure, there is provided a compound of formula (IV):



(IV)

or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein:

X is N or C;

Y is CH_2 or C=O;

R^{11} is hydrogen, -CO(C_1-C_6)alkyl, -CO(C_3-C_6)cycloalkyl, -CO(C_6-C_{10})aryl, -NHCO(C_1-C_6)alkyl, -$(CH_2)_n$-phenyl, -SO_2(C_1-C_6)alkyl, -SO_2(C_3-C_6)cycloalkyl, or -SO_2(C_6-C_{10})aryl, wherein the alkyl, aryl or heteroaryl portion of each of the groups may be optionally substituted with one or more halogen, hydroxyl or -(C_1-C_6)alkoxy;

R^{12} is -CO(C_1-C_6)alkyl, -CO(C_3-C_6)cycloalkyl, -CO(C_6-C_{10})aryl, -NHCO(C_1-C_6)alkyl, -$(CH_2)_n$-phenyl, -SO_2(C_1-C_6)alkyl, -SO_2(C_3-C_6)cycloalkyl, or -SO_2(C_6-C_{10})aryl, wherein the alkyl, aryl or heteroaryl portion of each of the groups may be optionally substituted with one or more halogen, hydroxyl or -(C_1-C_6)alkoxy;

R^{13} is hydrogen or -(C_1-C_6)alkyl; and

n is 0, 1, 2 or 3.

[13b] In another aspect of the present disclosure, there is provided a pharmaceutical composition comprising the compound disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.


[13c] In a further aspect of the present disclosure, there is provided the disclosed herein, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, or the pharmaceutical composition of claim 5 for use in a method of treating, managing or preventing a disease or disorder, wherein the disease or disorder is cancer, a disorder associated with angiogenesis, pain, macular degeneration or a related syndrome, a skin disease, a pulmonary disorder, an asbestos-related disorder, a parasitic disease, an immunodeficiency disorder, a CNS disorder, CNS injury, atherosclerosis or a related disorder, dysfunctional sleep or a related disorder, an infectious disease, hemoglobinopathy or a related disorder, or a TNFα related disorder.

[14] Also provided are methods of treating and managing various diseases or disorders. The methods comprise administering to a patient in need of such treatment or management a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt, solvate, prodrug, clathrate, or stereoisomer thereof.

[15] Further provided are methods of preventing various diseases and disorders, which comprise administering to a patient in need of such prevention a prophylactically

CLAIMS

1. A compound of formula (IV):



(IV)

or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein:

X is N or C;

Y is CH_2 or C=O;

R^{11} is hydrogen, -CO(C_1-C_6)alkyl, -CO(C_3-C_6)cycloalkyl, -CO(C_6-C_{10})aryl, -NHCO(C_1-C_6)alkyl, -$(CH_2)_n$-phenyl, -SO_2(C_1-C_6)alkyl, -SO_2(C_3-C_6)cycloalkyl, or -SO_2(C_6-C_{10})aryl, wherein the alkyl, aryl or heteroaryl portion of each of the groups may be optionally substituted with one or more halogen, hydroxyl or -(C_1-C_6)alkoxy;

R^{12} is -CO(C_1-C_6)alkyl, -CO(C_3-C_6)cycloalkyl, -CO(C_6-C_{10})aryl, -NHCO(C_1-C_6)alkyl, -$(CH_2)_n$-phenyl, -SO_2(C_1-C_6)alkyl, -SO_2(C_3-C_6)cycloalkyl, or -SO_2(C_6-C_{10})aryl, wherein the alkyl, aryl or heteroaryl portion of each of the groups may be optionally substituted with one or more halogen, hydroxyl or -(C_1-C_6)alkoxy;


R^{13} is hydrogen or -(C_1-C_6)alkyl; and


n is 0, 1, 2 or 3.


2. The compound of claim 1, wherein X is N.


3. The compound of claim 1, wherein Y is CH_2.


4. The compound of claim 1, which is:






























































or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.

5. A pharmaceutical composition comprising the compound of any one of claims 1-4, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

6. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, or the pharmaceutical composition of claim 5 for use in a method of treating, managing or preventing a disease or disorder, wherein the disease or disorder is cancer, a disorder associated with angiogenesis, pain, macular degeneration or a related syndrome, a skin disease, a pulmonary disorder, an asbestos-related disorder, a parasitic disease, an immunodeficiency disorder, a CNS disorder, CNS injury, atherosclerosis or a related disorder, dysfunctional sleep or a related disorder, an infectious disease, hemoglobinopathy or a related disorder, or a TNFα related disorder.